NasdaqGS - Delayed Quote USD

CytomX Therapeutics, Inc. (CTMX)

1.7000 -0.0500 (-2.86%)
At close: May 31 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
119,178.0000
101,214.0000
53,163.0000
37,312.0000
68,427.0000
--
Operating Expense
108,352.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
--
Operating Income
10,826.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
--
Net Non Operating Interest Income Expense
9,704.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
--
Other Income Expense
-56.0000
-30.0000
340.0000
-83.0000
-27.0000
--
Pretax Income
20,474.0000
3,323.0000
-99,317.0000
-115,870.0000
-78,731.0000
--
Tax Provision
3,941.0000
3,892.0000
--
--
-13,911.0000
--
Net Income Common Stockholders
16,533.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
--
Diluted NI Available to Com Stockholders
16,533.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
--
Basic EPS
0.21
--
-1.51
-1.81
-1.40
-2.93
Diluted EPS
0.21
--
-1.51
-1.81
-1.40
-2.93
Basic Average Shares
77,753.3560
--
65,739.8440
64,146.8480
46,145.5630
45,335.9270
Diluted Average Shares
77,903.4940
--
65,739.8440
64,146.8480
46,145.5630
45,335.9270
Total Operating Income as Reported
10,826.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
--
Total Expenses
108,352.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
--
Net Income from Continuing & Discontinued Operation
16,533.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
--
Normalized Income
16,533.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
--
Interest Income
9,704.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
--
Net Interest Income
9,704.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
--
EBIT
10,826.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
--
EBITDA
12,873.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
--
Reconciled Depreciation
2,047.0000
2,175.0000
2,443.0000
2,706.0000
2,573.0000
--
Net Income from Continuing Operation Net Minority Interest
16,533.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
--
Normalized EBITDA
12,873.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
--
Tax Rate for Calcs
0.0002
0.0002
--
--
0.0002
--
12/31/2019 - 10/8/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SPRO Spero Therapeutics, Inc.
1.4200
0.00%
 
ASMB Assembly Biosciences, Inc.
15.15
+1.95%
 
IKNA Ikena Oncology, Inc.
1.7700
-1.12%
 
CLRB Cellectar Biosciences, Inc.
3.0900
+1.64%
 
CYTK Cytokinetics, Incorporated
48.55
-1.16%
 
BBIO BridgeBio Pharma, Inc.
28.01
-2.91%
 
GLPG.AS Galapagos NV
25.34
-1.55%
 
MGNX MacroGenics, Inc.
4.0900
-3.54%
 
NXTC NextCure, Inc.
1.5400
-2.53%
 
AVRO AVROBIO, Inc.
1.4800
+2.78%